anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Although infant sleep regulation across the first year proceeds well for many infants, for many infants that is not the case, and estimates of sleep problems among infants and preschoolers range between 25%-33%. Dysregulated infant sleep is predictive of poor parent sleep, and chronic sleep disruption can place families in turmoil, with consequences for the marital and coparenting relationship. Further, mothers reporting early coparenting distress are at risk for personal distress and poor bedtime and nighttime parenting, which in turn predicts infant sleep problems and insecure infant attachment. This application proposes a randomized clinical trial (RCT) to evaluate the effects of a sleep-enhanced adaptation of an evidence-based transition-to-parenting coparenting intervention program \[Family Foundations - FF). The rationale for this study is twofold. First, recent findings from the PI's Project SIESTA (R01HD052809) indicate that poor coparenting at one month post-partum predicts persistent infant-parent co-sleeping across the first year, elevated maternal depressive symptoms, emotionally unavailable bedtime parenting, and insecure infant-mother attachments. Second, whereas FF as originally developed has been successful in improving coparenting, marital adjustment, and overall parenting quality, it gives little specific attention to coparenting in infant sleep contexts, which SIESTA findings identify as critically important to parent and infant outcomes later in the first year. The proposed 3-arm RCT responds to these concerns. In one arm, families will experience FF as originally formulated; in the second, families will receive an adapted FF that emphasizes coparenting in infant sleep contexts; the third arm will serve as controls. Assessments of coparenting and parenting in infant sleep contexts, parental adjustment to infant sleep behavior, choices about sleep arrangements, infant and parent sleep quality, and infant socio-emotional functioning, will serve as outcomes. Our central hypotheses are: (1) Compared to controls, parents in both FF groups will report improved overall coparenting and reduced overall distress, but parents in the adapted FF group will show greater improvements in coparenting and individual parenting in infant sleep contexts, better infant and parent sleep, and better child adjustment; (2) early coparenting around infant sleep will be a central mechanism by which both interventions exert their effects. This research is foundational to a broader understanding of coparenting processes that underlie successful family transitions and contributes to the refinement of a successful coparenting program. Study results will be of immediate use to obstetric and pediatric services interested in augmenting childbirth education material with information on coparenting practices in infant sleep contexts.
A cosmetic agent for the temporary shaping of keratinic fibers (e.g. hair), comprising a) a cosmetic preparation containing a1) and a2). A1 is at least one copolymer, made up of at least the following monomer units: N-tert-octylacrylamide, acrylic acid, tert-butylaminoethyl methacrylate, and a2 is at least one copolymer, made up of at least the following monomer units: (meth)acrylic acid, (meth)acrylic acid alkyl ester, (meth)acrylic acid hydroxyalkyl ester, wherein the weight proportion of copolymers a1) and a2) in terms of the total weight of the cosmetic preparation is 10 to 30% by weight. It is preferable that the cosmetic composition also comprises ethanol (50 to 85 wt.%) and water (5.0 to 25 wt.%). Preferably, the agent comprises at least one propellant. Also claimed is the use of the agent for the temporary shaping of keratin-containing fibres and a method for shaping keratin-containing fibres in which the agent is added to said keratinic fibres.
Anti-bacterial and anti-inflammatory cares are important in dental and oral clinics for prevention of bacterial infection and inflammation after oral and dental surgery, accompanied with dental swelling, bleeding, and pharyngolaryngitis within oral cavity. Same application of Anti-bacterial and anti-inflammatory cares are also used in anti-acne and cosmetics on body surface. Herbal preparations (HBHPBaicalin) with high level of baicalin are prepared from the mixture of Coptidis rhizome, Scutellariae radix and Rhei rhizome. The present study aimed to determine the preventive effects of standardized HBHPBaicalin on Lipopolysaccharides (LPS)-induced arterial hypotension, protein expression of iNOS and cyclooxygenase-2 (COX-2), cytokines formation and prostaglandin E2 (PGE2) production. LPS-induced activation of inducible nitric oxide synthase (iNOS) has been recognized to increase cytokines and nitric oxide, which of them play the predominant roles in sepsis. Intravenous injection of LPS caused a marked decrease of the mean arterial pressure in normotensive rats. However, the LPS-induced arterial hypotension was inhibited by HBHPBaicalin, when which was given 30 min before LPS. Moreover, plasma level of cytokines and PGE2 were lowered by HBHPBAICALIN. In RAW264.7 cells, HBHPBaicalin dose-dependently inhibited LPS-induced iNOS and COX-2 expression, and it also significantly decreased LPS-induced cytokines in a dose-dependent manner. In conclusion, these data suggest that HBHPBaicalin prevented LPS-induced arterial hypotension, which might be mediated through its inhibition activities on the expression of iNOS and COX-2, cytokines formation and prostaglandins production. Therefore, its protection activity against LPS-induced arterial hypotension and inflammatory mediators release might be beneficial in the treatment of endotoxin-associated inflammation. In this invention, HBHPBaicalin is further combined with menthol, alcohol, perfume, sorbitol, propylene glycol, metallic salt, ethanolamine, glycerin, sugar and other additives in gargle preparation or combined with sorbitol, hydrated silica, glycerin, sodium lauryl sufate, carrageenan, flavor, bee propolis, sodium saccharin, sodium benzoate, chlorophyllin-copper complex in toothgel preparation. HBHPBaicalin, combined with sugar, glucose, and corn starch, is also used in candy; it's combination with ointment is used for anti-acne on face. Key words: HBHPBaicalin; LPS; iNOS; COX-2; cytokines; PGE2; antibacterial; anti-inflammation
Semirigid instrument which we compare was autoclavable Olympus LTF-160 (Olympus Tokyo, Japan). Handle and its controls were similar to flexible fiberoptic bronchoscope, with the insertion portion composed of 22 cm long rigid part and distal 5 cm flexible tip with angulation range 1600 up / 1300 down. The external diameter of insertion portion was 7 mm with 2,8 mm inner channel diameter. The instrument was compatible with Olympus EVIS Exera 160 and 145 and EVIS 100 and 140 video processors and light sources, otherwise employed in video-bronchoscopy. Forceps, which we used was flexible FB-55CD-1 Olympus forceps with 5 mm long cusps and diameter, which fitted the diameter of inner channel of semirigid thoracoscope.
Systems and methods for tracking samples via sample tracking chains are presented. Sample tracking chains represent digital data structures instantiated according to intrinsic properties of a sample. Each link in the chain is a block of data representing an observed intrinsic state of the sample and is linked at least to a previous block representing a previous state. The sample tracking chain and blocks can be indexed for later retrieval by the intrinsic properties of the corresponding sample's state. The sample tracking chain can take the form of a blockchain possibly stored as part of a private or public distributed ledger. Disclosed sample tracking chains provide a full life cycle audit trail for sample processing.
ENP: The health centers were strengthened to provide WHO/FMOH-recommended nutrition interventions in pregnancy. Pregnant women received a supply of adequately iodized salt for household use and iron-folate tablets from enrollment to birth. Women with undernutrition (MUAC \<23 cm), also received a daily balanced energy protein supplement. Standard infection care: Maternal genitourinary tract infections is managed as per standard FMOH health center guidelines that utilize a syndromic management approach.
Body temperature, pulse, arterial blood pressure, SPO2 will be measured and recorded every fifteen minutes in the control group one hour before the operation. The patients in the control group will not be dressed in warm socks and general preparations will be made. During the operation, the patient's body temperature, pulse, arterial blood pressure, SPO2 values will be monitored every fifteen minutes and the total amount of drainage during the operation will be recorded in the same department. Body temperature, pulse, arterial blood pressure, SPO2 values, tremors, and total drainage in the postoperative care unit will be recorded every fifteen minutes. Body temperature, heart rate, arterial blood pressure, SPO2 values will be measured after transferring to the bed and every fifteen minutes for a total of 180 minutes, chills, shivering states, and 24-hour total drainage amount will be recorded in the same section.
L 7053 (R) ABSTRACT            The oxidative stability of esters of unsaturated fatty acids and polyols having from 4-8 hydroxyl groups, preferably of sugars or sugar alcohols, more preferably of sucrose, is improved if the esters contain an effective amount of the trans-unsaturated fatty acid chains.            If more than 50% of the hydroxyl groups of the polyols are esterified, the esters can be used as low-calorie fat replacers, which in the case of sucrose with at least 4 hydroxyl groups esterified are called SPE (sucrose polyesters). If only 1-3 hydroxyl groups are esterified, the esters can act as emulsifiers.            The ratio of cis:trans double bonds preferably ranges from (20:80) to (40:60), more preferably from (30:70) to (35:65). The trans-unsaturated fatty acid esters of polyols can be used in an amount of 0.5-99% of an edible composition, either as an emulsifier or as a fat replacer.                            ***
A user interface may be provided for displaying a series of reports. The user interface may include a primary report area, a secondary report area and a navigation slider. The primary report area may be utilized to display a selected report image associated with a report in a report series. The secondary report area may be utilized to display one or more additional report images associated with other reports in the report series. The navigation slider may be utilized to navigate among the report images displayed in the secondary report area. The report images displayed in the primary and secondary report areas may be manipulated by one or more user commands received in the user interface.
The present invention is in the field of personal care compositions; in particular skin lightening compositions. It is believed that niacinamide reduces the melanosome transfer from melanocytes to keratinocytes thereby bringing about skin lightening. However, niacinamide is known to have little or no effect directly on the melanin content in the melanocytes. Thus a composition with multiple modes of action, that combines the reduction of melanosome transfer and the reduction of melanin content in the melanocytes remains to be desired. It is therefore an object of the present invention to provide a composition with synergistic amounts of picolinamide and niacinamide, providing improved melanosome transfer inhibition. It has been found that a synergistic skin lightening effect is obtained when niacinamide is combined with its isomer, picolinamide.
Arm I - Patients undergo COE followed by DVFE. Patients with tissue abnormalities found by COE or DVFE undergo biopsy within 2 weeks.
We investigated the role that innate immunological signaling pathways, principally nod-like receptors (NLRs) and inflammasomes, in the manifestation of the contradictory outcomes associated with opioids, namely hyperalgesia, and tolerance. The utilization of opioids for pain management is prevalent; nonetheless, it frequently leads to an increased sensitivity to pain (hyperalgesia) and reduced efficacy of the medication (tolerance) over an extended period. This, therefore, represents a major challenge in the area of chronic pain treatment. Recent studies indicate that the aforementioned negative consequences are partially influenced by the stimulation of NLRs, specifically the NLRP3 inflammasome, and the subsequent assembly of the inflammasome. This process ultimately results in the generation of inflammatory cytokines and the occurrence of neuroinflammation and the pathogenesis of hyperalgesia. We also explored the putative downstream signaling cascades activated by NOD-like receptors (NLRs) and inflammasomes in response to opioid stimuli. Furthermore, we probed potential therapeutic targets for modifying opioid-induced hyperalgesia, with explicit emphasis on the activation of the NLRP3 inflammasome. Ultimately, our findings underscore the significance of conducting additional research in this area that includes an examination of the involvement of various NLRs, immune cells, and genetic variables in the development of opioid-induced hyperalgesia and tolerance. The present review provides substantial insight into the possible pathways contributing to the occurrence of hyperalgesia and tolerance in individuals taking opioids.
Genetic mosaicism has long been linked to aging, and several hypotheses have been proposed to explain the potential connections between mosaicism and susceptibility to cancer. It has been proposed that mosaicism may disrupt tissue homeostasis by affecting intercellular communications and releasing microenvironmental constraints within tissues. The underlying mechanisms driving these tissue-level influences remain unidentified, however. Here, we present an evolutionary perspective on the interplay between mosaicism and cancer, suggesting that the tissue-level impacts of genetic mosaicism can be attributed to Indirect Genetic Effects (IGEs). IGEs can increase the level of cellular stochasticity and phenotypic instability among adjacent cells, thereby elevating the risk of cancer development within the tissue. Moreover, as cells experience phenotypic changes in response to challenging microenvironmental conditions, these changes can initiate a cascade of nongenetic alterations, referred to as Indirect non-Genetic Effects (InGEs), which in turn catalyze IGEs among surrounding cells. We argue that incorporating both InGEs and IGEs into our understanding of the process of oncogenic transformation could trigger a major paradigm shift in cancer research with far-reaching implications for practical applications.
PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 200 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
Gastric emptying scintigraphy is considered the gold standard for evaluating gastric emptying and is widely available. Accurate characterization of gastric emptying may guide medical and surgical treatment choices. In addition, these techniques may allow for monitoring of therapeutic results for follow-up patient management.

The SmartPill GI Monitoring System offers an alternative non-invasive method for characterizing disorders of the stomach. The system consists of an ingestible capsule that houses sensors for pH, temperature, and pressure, a receiver for receiving and storing signals from the capsule, and software for displaying data on a personal computer. The capsule samples at regular intervals and transmits the sensed pH, pressure, and temperature data to a portable receiver worn by the subject. After test completion, the recorded data is downloaded to a personal computer for subsequent evaluation.
Four groups of up to 12 participants (48 total) will receive the study intervention during Spring and Fall 2022. All participants will complete study questionnaires before and after the sessions.
<P>PROBLEM TO BE SOLVED: To obtain a topical anti-oxidant composition for protecting the skin from damage induced by ultraviolet radiation.  <P>SOLUTION: The composition comprises a first component (such as β-glucan and a grape seed extract) which increases the cellular viability of epidermal cells and a second component which decreases the production of inflammatory mediators such as prostaglandins in those cells. In a particular embodiment, the composition comprises β-glucan in combination with panthenol, a grape seed extract, vitamin C, and superoxide dismutase which exhibit a synergistic effect in protecting the skin from the adverse effects of ultraviolet radiation. In another embodiment, the composition further comprises vitamin A and vitamin E. In a further embodiment, the composition comprises a combination of one or more anti-oxidants and sunscreen agents in an emulsion such as a water-in oil (W/O) type emulsion which provides superior protection of the skin against the harmful effects of ultraviolet radiation. These anti-oxidant compositions are incorporated into sunscreen products, soaps, moisturizing lotions, skin conditioning agents, and other skin care products.  <P>COPYRIGHT: (C)2008,JPO&INPIT
PURPOSE: To obtain a percutaneous drug-delivering device capable of releasing a drug at a speed and a time lag which are controlled at specified levels by a time-lag controlling membrane, enabling the prevention of the occurrence of resistance during a therapy with the adjustment of the treating time or a multiple continuous therapy and able to control a treating time. CONSTITUTION: A pharmaceutically active agent (drug) is dispersed in a drug storing layer body 2 made of a polymer base material, and this is protected from the environmental condition by an impermeable packing membrane l. An adhesive layer 3 is optionally attached under the drug storing layer body 2. The drug storing layer body 2 and a permeable time-lag controlling membrane 6 are separated from each other by an impermeable separation membrane 4 consisting of a removable impermeable membrane. The impermeable separation membrane 4 is removed from the main body device just before use, and the main body is attached to the skin surface by an adhesive layer 5. The adhesive layers 3 and 5 are optionally added, however the permeability resistances through the adhesive layers are negligible. The time-lag of drug release is controlled by the inner structure and the thickness of the time-lag controlling membrane 6 at will.
1,154,359. Hydrogenated moenomycins. FARBWERKE HOECHST A.G. 2 Sept., 1966 [3 Sept., 1965], No. 39324/66. Heading C2A. The antibiotic activity of moenomycin complex (Specification 977,327) or its components A, B and C against gram-positive pathogenic germs is enhanced by hydrogenation. The hydrogenation is carried out with the aid of precious metal catalysts (e.g. platinum) or Raney nickel in a polar solvent such as water, glacial acetic acid, methanol or dimethyl formamide. In the case of the hydrogenated moenomycin complex, the complex may be separated into the hydrogenated single components A, B and C by the process of Specification 1,126,196. Physical data for the hydrogenated compounds are provided. Pharmaceutical compositions comprise a carrier and a hydrogenated moenomycin complex or hydrogenated component A, B or C.
A single-step, one-pot process to obtain zotarolimus and other rapamycin derivatives on large scale that improves currently available syntheses. In one embodiment, dried rapamycin is dissolved in isopropylacetate . After cooling and 2,6-Lutidine addition, triflic anhydride is slowly added at -30° C. Salts are removed by filtration. Tetrazole, followed by a tert-base diisopropylethylamine is added. After incubation at room temperature, the product is concentrated and purified by a silica gel column using THF/heptane as eluant. The product is collected, concentrated, and purified using an acetone/heptane column. The product-containing fractions are concentrated. The product is dissolved in t-BME and precipitated with heptane. The solids are dissolved in acetone, treated with butylated-hydroxy toluene, and the solution concentrated. The process is repeated twice with acetone to remove solvents. At least one stabilizing agent is added, such as BHT at 0.5% before drying.
Up to 500 participants (including primary tumor location of pharynx, larynx, oral cavity and oropharynx) with metastatic or unresectable recurrent HNSCC who are intended for first line immunotherapy or combination therapy. No intervention.
The investigators will conduct feasibility testing of a 3 week sleep health promotion intervention. The intervention will be delivered to parents of children ages 12-36 months enrolled in one childcare center.
The invention relates to a hair dye mixture, containing (methyl)acrylate having a percent of 1wt%-15wt% and a molecular weight less than 100 g/mol and being water-soluble. The mixture also contains an oxide dye precursor, which has at least one colorant and at least one primary intermediary. The pH of the mixture is 8-12 and the mixture has no oxidant. The invention also relates to a hair dye preparation always available for use, the preparation contains (methyl)acrylate having a weight percent between 0.1wt% and 15wt%, wherein the molecular weight of the (methyl)acrylate is less than 100 g/mol and the (methyl)acrylate is water-soluble. The preparation also contains an oxide dye precursor which has at least one colorant and at least one primary intermediary. The preparation yet also has an oxidant. The pH of the mixture is 8-12.
Participants in the EE group will perform the overhead shrug exercise for the affected side using a green Thera-Band Elastic Band. To perform this exercise, the subject will stand and place one arm of the affected side in an overhead position against the wall. The middle portion of the theraband will be placed on the floor, and the subject will stand on the middle portion of the theraband to fixate it in place with both feet shoulder-width apart. Then, the subject grasp both tails of the theraband and perform the shoulder shrug movement for the affected side with a 3-second elevation, hold at the end range for 5 seconds, and then return back to the starting position with a 3-second depression. The subject will perform this exercise for 20 repetitions per set, 3 sets a day with 1-minute rest between sets, 3 alternate days a week, for 5 weeks. They will be instructed to record all training sessions in a diary.